We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

FDA Opts To Fast Track Constipation Drug

Law360 (July 17, 2006, 12:00 AM EDT) -- Trying to accelerate the regulatory review process, the U.S. Food and Drug Administration has decided to fast-track Wyeth Pharmaceuticals and Progenics Pharmaceuticals’ application for a drug intended to treat postoperative gastrointestinal impairment.

The FDA announced the move on Monday, revealing that it has awarded fast-track status to the intravenous form of methylnaltrexone, which would be used to minister to the postoperative ileus (POI) condition.

POI is an impairment of bowel motility that usually occurs after abdominal surgery.

The average duration of ileus after major abdominal surgery...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.